多发性硬化症患者体内针对糖基化天然髓鞘少突胶质细胞糖蛋白的抗体水平升高。
Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.
作者信息
Gaertner Susanne, de Graaf Katrien L, Greve Bernhard, Weissert Robert
机构信息
Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
出版信息
Neurology. 2004 Dec 28;63(12):2381-3. doi: 10.1212/01.wnl.0000147259.34163.33.
Antibodies against native glycosylated myelin-oligodendrocyte-glycoprotein (MOG) were measured by ELISA in patients with multiple sclerosis (MS) and controls. Anti-MOG IgM antibodies were elevated during the first demyelinating event. Higher MOG-specific IgG antibodies were found in patients during relapses and in secondary chronic progressive MS compared to patients in remission and healthy controls. Antibodies against native MOG may be a potential biomarker for MS.
通过酶联免疫吸附测定法（ELISA）检测了多发性硬化症（MS）患者和对照组中针对天然糖基化髓鞘少突胶质细胞糖蛋白（MOG）的抗体。在首次脱髓鞘事件期间，抗MOG IgM抗体升高。与缓解期患者和健康对照组相比，复发期患者以及继发慢性进展型MS患者体内发现了更高水平的MOG特异性IgG抗体。针对天然MOG的抗体可能是MS的一种潜在生物标志物。
Zotero 插件